O Shaughnessy Asset Management LLC Grows Holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

O Shaughnessy Asset Management LLC raised its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 11.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,710 shares of the specialty pharmaceutical company’s stock after purchasing an additional 8,475 shares during the quarter. O Shaughnessy Asset Management LLC’s holdings in Collegium Pharmaceutical were worth $2,312,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its position in shares of Collegium Pharmaceutical by 14.5% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the period. AlphaQuest LLC increased its stake in Collegium Pharmaceutical by 3.0% in the 4th quarter. AlphaQuest LLC now owns 12,780 shares of the specialty pharmaceutical company’s stock worth $366,000 after buying an additional 374 shares in the last quarter. Gallacher Capital Management LLC raised its holdings in Collegium Pharmaceutical by 3.3% during the fourth quarter. Gallacher Capital Management LLC now owns 14,571 shares of the specialty pharmaceutical company’s stock valued at $417,000 after acquiring an additional 470 shares during the period. TD Private Client Wealth LLC lifted its position in shares of Collegium Pharmaceutical by 39.5% in the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after acquiring an additional 483 shares in the last quarter. Finally, Caprock Group LLC boosted its stake in shares of Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company’s stock worth $249,000 after acquiring an additional 543 shares during the period.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Colleen Tupper sold 977 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $29,310.00. Following the completion of the sale, the chief financial officer now owns 164,269 shares of the company’s stock, valued at approximately $4,928,070. This represents a 0.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 109,193 shares of company stock worth $3,243,594. Corporate insiders own 3.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on COLL shares. Piper Sandler decreased their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 4th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a research note on Friday, January 10th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $43.60.

Collegium Pharmaceutical Stock Down 3.0 %

Shares of COLL opened at $28.14 on Friday. The business’s 50 day simple moving average is $30.02 and its 200-day simple moving average is $32.19. Collegium Pharmaceutical, Inc. has a 1 year low of $27.28 and a 1 year high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The stock has a market capitalization of $904.19 million, a price-to-earnings ratio of 12.13 and a beta of 0.76.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The business had revenue of $181.95 million during the quarter, compared to analyst estimates of $179.68 million. As a group, equities analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.